Stoke Therapeutics, Inc. revenue breakdown overview

Stoke Therapeutics, Inc. revenue for the last year amounted to 8.78 M USD, the most of which — 8.78 M USD — came from its highest performing source at the moment, Antisense Oligonucleotide, the year earlier bringing 12.40 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Stoke Therapeutics, Inc. 8.78 M USD, and the year before that — 12.40 M USD.